[Featured Stock] Eutilex Surges 15% on Smooth Progress in New Drug Clinical Trials

[Image source=Yonhap News]

[Asia Economy Reporter Ji Yeon-jin] UtilX's stock price surged sharply during the trading session on the 25th following news that the clinical trials of its new drug under development are progressing smoothly.

As of 10:22 AM on the same day, UtilX was trading at 8,970 KRW on the KOSPI market, up 15.89% (1,230 KRW) compared to the previous day.

Earlier, KB Securities released an analysis stating that the clinical trials of three new drug pipelines developed by UtilX are progressing well, which appears to have driven the sharp rise in the stock price.

UtilX is developing immuno-oncology drugs including antibody therapeutics, T-cell therapeutics, chimeric antigen receptor T-cell (CAR-T) therapeutics, and allogenic T-cell therapeutics.

Clinical researcher from KB Securities, Im, explained, "Phase 1/2 clinical trials for EU101 are underway in Korea and the United States," and added, "As an immune checkpoint activator specialized in T-cell activation and proliferation, high growth potential is expected."

He continued, "BMS and Pfizer have also developed 4-1BB targeting antibody therapeutics," but noted, "Clinical trials were halted due to liver toxicity issues and failure to prove efficacy."

Furthermore, he emphasized, "UtilX resolved toxicity issues through engineered IgG1 (immunoglobulin)," and stated, "So far, there have been no cases of toxicity or side effects."

Researcher Im analyzed, "Recent low-dose administration is expected to yield excellent therapeutic effects," and added, "When combined with immune checkpoint inhibitors such as Keytruda, significant synergy and therapeutic effects are anticipated."